Remarkable recent advances have revolutionized the field of heart failure. Survival has
improved among individuals with heart failure and a reduced ejection fraction and for the …

Heart failure (HF) with preserved ejection fraction (HFpEF) is an increasingly frequent form
and is estimated to be the dominant form of HF. On the other hand, HFpEF is a syndrome …

Heart failure with preserved ejection fraction (HFpEF) is increasingly recognised and
diagnosed in clinical practice, a trend driven by an ageing population and a rise in …

Aims Cardiovascular‐kidney‐metabolic (CKM) multimorbidity is prevalent among individuals
with heart failure (HF), but whether cardiac structure and function, clinical outcomes, and …

This review serves to compare contemporary clinical practice recommendations for the
management of heart failure (HF), as codified in the 2021 European Society of Cardiology …

Despite major advances in prevention and medical therapy, heart failure (HF) remains
associated with high morbidity and mortality, especially in older and frailer patients …

Synergistic effects of MRA and SGLT2i in HF: Key beneficial effects (+) of mineralocorticoid
receptor antagonists (MRA) and sodium–glucose co-transporter inhibitors (SGLT2i) on …

Heart failure is increasing in prevalence in many countries with aging populations.
Fortunately, remarkable scientific advances have been made in the past few years that have …

In the last years, major progress has occurred in heart failure (HF) management. The 2023
ESC focused update of the 2021 HF guidelines introduced new key recommendations …

Background Three medications are now guideline-recommended treatments for heart failure
with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF), however, the cost …